News

Interview of Petrovax President Mikhail Tsyferov for Bloomberg

Slovakia joins the international clinical trials of polyoxidonium for treating covid-19

Petrovax and Intellogic launch a project to use the Botkin.AI platform for studying the effect of Longidaze® among patients recovered from COVID-19

Petrovax helps the Podolsk City Clinical Hospital equip a new hospital against COVID-19

PETROVAX INTRODUCES URONEXT® – A NEW PRODUCT AGAINST CYSTITIS ON THE RUSSIAN MARKET

Mikhail Tsyferov spoke about the challenges, opportunities and prospects faced by the pharmaceutical industry during the pandemic at the RussiaTALK Online 2020 Forum

Mikhail Tsyferov speaks about international drug studies and COVID-19 vaccine manufacturing prospects in Russia at the 5th GMP conference

THE FIRST GROUP OF VOLUNTEERS ARE VACCINATED WITH AD5-NCOV CANDIDATE VACCINE IN RUSSIA

Artem Levankov, Vice President on Economics and Finance of Petrovax, took part in Pharma CFO 2020 online conference of chief financial officers of pharmaceutical business

PETROVAX AND CANSINO BIOLOGICS ARE TO LAUNCH PHASE III INTERNATIONAL CLINICAL TRIAL OF THE POTENTIAL COVID-19 VACCINE IN RUSSIA

Petrovax President Mikhail Tsyferov shared the details of a large-scale trial program of Polyoxidonium® in the COVID-19 context at the National Forum "The Nation’s Health as the Foundation for a Flourishing Russia"

INTERNATIONAL CLINICAL TRIAL OF POLYOXIDONIUM CONFIRMS ITS SAFETY FOR COVID-19 TREATMENT

Petrovax congratulated Podolsk physicians on Health Worker Day

Petrovax helps doctors during COVID-19 pandemic

Russian Petrovax ramps up pharmaceutical production driven by COVID-19 pandemic

Polyoxidonium (INN: azoximer bromide) has been included into Temporary Guidelines for ARVI during COVID-19 pandemic

COVID-19: Petrovax launched an international clinical trial of Polyoxidonium for novel coronavirus infection